Recent News

• 05.12.2026 - OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
• 05.12.2026 - OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
• 04.30.2026 - OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
• 04.30.2026 - OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
• 04.30.2026 - BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
• 04.30.2026 - BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
• 04.28.2026 - OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
• 04.28.2026 - OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
• 04.22.2026 - OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
• 04.22.2026 - OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

Recent Filings

• 04.30.2026 - ARS Annual Report to Security Holders
• 04.30.2026 - DEF 14A Other definitive proxy statements
• 04.30.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.28.2026 - 8-K Current report
• 04.28.2026 - EX-99.1 EX-99.1
• 04.28.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]